Hematologic Malignancy
Monoclonal Immunoglobulin Deposition Disease
CI-CAN-00006049Explore in graph →
HematologicNon-malignant37 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006049Explore in graph →
Clinical trials
149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06935162 | Teclistamab in Previously Treated AL Amyloidosis | recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06699394 | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis | recruiting | N/A | 20 | Peking University People's HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| Daratumumab for Patients With Light Chain Amyloidosis |
| recruiting |
| N/A |
| 100 |
| Nanjing University School of MedicineOTHER |
| 1 |
| Apr 19, 2024 |
| clinicaltrials |
| NCT04210791 | Autologous Stem Cell Transplantation for Patients With AL Amyloidosis | enrolling by invitation | — | 500 | Nanjing University School of MedicineOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06065852 | National Registry of Rare Kidney Diseases(RaDaR) | recruiting | — | 35,000 | UK Kidney AssociationOTHER | 1 | Oct 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 25, 2025source: clinicaltrials